Explore
Validate
Learn3696
antibody from Cell Signaling Technology, Inc
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 3696 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#3696, RRID:AB_10692107
- Product name
- DR5 Antibody
- Antibody type
- Polyclonal
- Reactivity
- Human
- Host
- Rabbit
- Storage
- -20°C
Submitted references FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.
Hedgehog signaling drives cellular survival in human colon carcinoma cells.
Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1.
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Huang Y, Jin H, Liu Y, Zhou J, Ding J, Cheng KW, Yu Y, Feng Y
Endocrine-related cancer 2011 Feb;18(1):13-26
Endocrine-related cancer 2011 Feb;18(1):13-26
Hedgehog signaling drives cellular survival in human colon carcinoma cells.
Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA
Cancer research 2011 Feb 1;71(3):1092-102
Cancer research 2011 Feb 1;71(3):1092-102
Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Tian X, Ye J, Alonso-Basanta M, Hahn SM, Koumenis C, Dorsey JF
The Journal of biological chemistry 2011 Aug 19;286(33):29408-16
The Journal of biological chemistry 2011 Aug 19;286(33):29408-16
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M
Molecular cancer therapeutics 2010 Sep;9(9):2582-92
Molecular cancer therapeutics 2010 Sep;9(9):2582-92
Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1.
Lee MS, Cherla RP, Lentz EK, Leyva-Illades D, Tesh VL
Infection and immunity 2010 Aug;78(8):3378-91
Infection and immunity 2010 Aug;78(8):3378-91
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Mar 15;15(6):2048-57
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Mar 15;15(6):2048-57
No comments: Submit comment
No validations: Submit validation data